Acurx Pharmaceuticals announces positive data from phase 2b trial for C. difficile infection treatment
October 3, 2023Research and Development Acurx Pharmaceuticals, C. difficile, Infections and infestations, clinical trial, infection
Acurx Pharmaceuticals has announced that it has discontinued its phase 2b clinical trial of its lead antibiotic candidate, ibezapolstat, for …
WHO recommends new vaccine for prevention of malaria in children
October 3, 2023Medical Communications Immunology, Vaccine, WHO, malaria, malaria vaccine
The World Health Organization (WHO) has announced that it has recommended a new vaccine, R21/Matrix-M, for the prevention of malaria …
FDA grants marketing authorisation to DNA test for predisposition to certain cancers
October 2, 2023Research and Development FDA, Invitae, Oncology, cancer testing, oncology
The US Food and Drug Administration (FDA) has granted de novo marketing authorisation to the Invitae Common Hereditary Cancers Panel, …
Biogen’s biosimilar Tofidence approved by FDA
October 2, 2023Medical Communications Actemra, Biogen, FDA, Musculo-skeletal disorder, Tofidence
Biogen has announced that the US Food and Drug Administration (FDA) has approved Tofidence (tocilizumab-bavi) as an intravenous formulation, a …
Austrian state secretary to speak at FlyPharma Europe 2023
September 29, 2023Business Services FlyPharma 2023, Vienna, flypharma
29 September 2023 — London, UK — FlyPharma Europe will welcome Mr Florian Tursky, the Austrian state secretary, to the …
Karuna Therapeutics submits NDA to FDA for schizophrenia treatment
September 29, 2023Medical Communications FDA, Karuna Therapeutics, Neurology, mental health, schizophrenia
Karuna Therapeutics has announced that it has submitted a New Drug Application (NDA) to the US Food and Drug Administration …
Kura Oncology shares preclinical data for NSCLC treatment
September 29, 2023Medical Communications Kura Oncology, NSCLC, Oncology, oncology
Kura Oncology has shared positive preclinical data which supports the development of its next-generation farnesyl transferase inhibitor (FTI) KO-2806 in …
BactiVac funds development of bacterial vaccines to prevent infections against antimicrobial resistance
September 28, 2023Research and Development AMR, BactiVac, Immunology, vaccines
The University of Birmingham hosted Bacterial Vaccines Network has been awarded £1.4m in funding from the UK government to accelerate …
Avalyn Pharma raises $175m in Series C financing for inhalation therapies
September 28, 2023Business Services Avalyn Pharma, Financing, Pharmacy, funding, inhalation therapies
US-based clinical stage biopharmaceutical company Avalyn Pharma has announced that it has raised $175m in Series C financing to continue …
NMD Pharma begins phase 2 trial for spinal muscular atrophy treatment
September 27, 2023Research and Development Musculo-skeletal disorder, NMD Pharma, clinical trial, spinal muscular atrophy
NMD Pharma has announced that the first patient has been dosed in its phase 2 clinical trial for its CIC-1 …
Alfasigma to acquire Intercept Pharmaceuticals for $19 per share
September 27, 2023Business Services Alfasigma, Gastrointestinal tract, acquisition
Alfasigma and Intercept Pharmaceuticals have announced that they have entered into a definitive merger agreement, meaning Alfasigma will acquire Intercept …
Regeneron and Sanofi’s sBLA for Dupixent accepted by FDA for priority review
September 26, 2023Medical Communications Dupixent, Ear Nose & throat, FDA, Regeneron, Sanofi
Regeneron Pharmaceuticals and Sanofi have announced that the US Food and Drug Administration (FDA) has accepted their supplemental Biologics License …
Acesion Pharma raises €45m series B funding
September 26, 2023Business Services Acesion Pharma, Cardiology, atrial fibrillation, series B financing
Acesion Pharma has announced that it has closed an oversubscribed €45m series B financing round. This financing was co-led by …
CDC Advisory Committee recommends Pfizer’s RSV vaccine
September 25, 2023Medical Communications Abrysvo, Immunology, Pfizer, RSV
Pfizer has announced that the US Centers for Disease Control and Prevention’s (CDC) Advisory Committee on Immunization Practices (ACIP) has …
FDA approves Eli Lilly and Boehringer Ingelheim’s Jardiance for chronic kidney disease treatment
September 25, 2023Medical Communications Boehringer Ingelheim, Eli Lilly, FDA, Nephrology, chronic kidney disease
Eli Lilly and Boehringer Ingelheim have announced that the US Food and Drug Administration (FDA) has approved Jardiance (empagliflozin) 10mg …
FDA grants ODD to Nexcella’s NXC-201 as treatment for amyloid light chain amyloidosis
September 22, 2023Medical Communications FDA, Haematology, Nexcella, amyloidosis
Nexcella has announced that the US Food and Drug Administration (FDA) has granted orphan drug designation (ODD) to NXC-201 for …
AstraZeneca and Daiichi Sankyo’s datopotamab deruxtecan performs well in phase 3 trial
September 22, 2023Research and Development AstraZeneca, Daiichi Sankyo, Oncology, breast cancer, clinical trial
AstraZeneca and Daiichi Sankyo have shared positive high-level results from the TROPION-Breast01 phase 3 trial, which showed datopotamab deruxtecan (Dato-DXd) …
Novo Nordisk partners with UNICEF to prevent global childhood obesity
September 21, 2023Medical Communications Novo Nordisk, Obesity, Unicef, childhood obesity
Novo Nordisk and UNICEF have announced an extension to their long-term partnership aiming to prevent global childhood obesity, which is …
EC approves Menarini Group’s Orserdu for breast cancer treatment
September 21, 2023Medical Communications European Commission, Oncology, Orserdu, breast cancer
The Menarini Group and its subsidiary Stemline Therapeutics have announced that the European Commission (EC) has approved Orserdu (elacestrant) as …
Pharmanovia acquires CNS portfolio from Sanofi
September 20, 2023Medical Communications CNS, Neurology, Pharmanovia, Sanofi, acquisition
Pharmanovia has announced that it will expand its neurology portfolio with the acquisition of a selection of central nervous system …
Latest content
Long-acting therapies set to reshape HIV treatment market
MHRA approves Romvimza for tenosynovial giant cell tumour
